ArmaGen, Inc., a privately held biotechnology company focused on developing therapies to treat severe neurological disorders, announced that the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development granted Orphan Drug Designation to AGT-184 for the treatment of mucopolysaccharidosis type IIIA (also known as Sanfilippo Syndrome A or MPS IIIA). MPS IIIA is a…